Qtron Investments LLC Has $1.16 Million Position in Dr.Reddy’s Laboratories Ltd (NYSE:RDY)

Qtron Investments LLC grew its position in Dr.Reddy’s Laboratories Ltd (NYSE:RDY) by 268.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,728 shares of the company’s stock after acquiring an additional 20,928 shares during the period. Dr.Reddy’s Laboratories comprises about 1.1% of Qtron Investments LLC’s portfolio, making the stock its 14th largest holding. Qtron Investments LLC’s holdings in Dr.Reddy’s Laboratories were worth $1,163,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. BlackRock Inc. raised its stake in Dr.Reddy’s Laboratories by 14.0% in the 4th quarter. BlackRock Inc. now owns 1,978,415 shares of the company’s stock worth $74,588,000 after purchasing an additional 242,856 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Dr.Reddy’s Laboratories by 0.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 921,688 shares of the company’s stock worth $34,751,000 after purchasing an additional 3,272 shares in the last quarter. Mondrian Investment Partners LTD raised its stake in Dr.Reddy’s Laboratories by 4.7% in the 1st quarter. Mondrian Investment Partners LTD now owns 609,187 shares of the company’s stock worth $24,672,000 after purchasing an additional 27,260 shares in the last quarter. Parametric Portfolio Associates LLC raised its stake in Dr.Reddy’s Laboratories by 17.0% in the 1st quarter. Parametric Portfolio Associates LLC now owns 562,532 shares of the company’s stock worth $22,783,000 after purchasing an additional 81,828 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Dr.Reddy’s Laboratories by 3.9% in the 4th quarter. Northern Trust Corp now owns 415,086 shares of the company’s stock worth $15,649,000 after purchasing an additional 15,395 shares in the last quarter. 12.73% of the stock is owned by institutional investors.

Several analysts have weighed in on RDY shares. Zacks Investment Research upgraded shares of Dr.Reddy’s Laboratories from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a research note on Tuesday, March 19th. Morgan Stanley cut shares of Dr.Reddy’s Laboratories from an “overweight” rating to an “equal weight” rating in a research note on Monday, May 20th. TheStreet cut shares of Dr.Reddy’s Laboratories from a “b” rating to a “c” rating in a research note on Monday, May 20th. Barclays initiated coverage on shares of Dr.Reddy’s Laboratories in a research note on Tuesday, June 11th. They issued an “equal weight” rating and a $39.00 price objective for the company. Finally, Deutsche Bank initiated coverage on shares of Dr.Reddy’s Laboratories in a report on Thursday, June 20th. They issued a “hold” rating on the stock. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the company’s stock. Dr.Reddy’s Laboratories has an average rating of “Hold” and a consensus price target of $41.50.

Shares of Dr.Reddy’s Laboratories stock traded down $0.18 during midday trading on Friday, hitting $37.47. 194,652 shares of the company traded hands, compared to its average volume of 188,709. The stock has a market capitalization of $6.25 billion, a PE ratio of 22.85 and a beta of 0.24. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.36 and a current ratio of 1.92. The business has a fifty day simple moving average of $38.13. Dr.Reddy’s Laboratories Ltd has a 12 month low of $29.00 and a 12 month high of $42.82.

Dr.Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Friday, May 17th. The company reported $0.38 earnings per share (EPS) for the quarter. The company had revenue of $581.00 million for the quarter, compared to analyst estimates of $565.46 million. Dr.Reddy’s Laboratories had a net margin of 12.20% and a return on equity of 13.85%. As a group, equities research analysts predict that Dr.Reddy’s Laboratories Ltd will post 1.69 earnings per share for the current year.

Dr.Reddy’s Laboratories Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Further Reading: Why does the United States have a lingering trade deficit?

Institutional Ownership by Quarter for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.